Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesImpact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
International Journal of Rheumatic Diseases, 08/19/09
The BONADASIA study group – The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) had no further impact on increasing adherence, but increased treatment satisfaction.
Methods- Study to assess the impact of serum CTX BMF on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis
- A 12-mo (6-monthly phased), trial conducted in 596 (of 628 enrolled) pts (≤85 yrs old) who were naïve, lapsed, or current bisphosphonate users
- Pts were randomized into 2 arms: serum CTX BMF at 3 mo vs no-BMF
- Once-monthly 150 mg ibandronate tablet was administered for 12 mo and adherence to therapy was assessed at 6 and 12 mo
- In addition, patient satisfaction and safety of ibandronate treatment were also assessed
- Serum CTX BMF at 3 mo showed no impact on adherence
- Proportions of adherent pts were comparable in the BMF vs no-BMF arms
- Overall, serum CTX levels were similar for adherent and non-adherent pts
- However, BMF pts felt more informed about their osteoporosis and more satisfied than no-BMF pts
Related Articles
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study
Journal of Bone and Mineral Metabolism, 11/09/09
Relevance Score: 88%
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09
Relevance Score: 82%
Evaluation of bone mineral density and bone turnover markers in Egyptian children with juvenile rheumatoid arthritis
Archives of Medical Science, 11/03/09
Relevance Score: 81%
Nutrition and bone: it is more than calcium and vitamin D
Women's Health, 11/04/09
Relevance Score: 80%
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/23/09
Relevance Score: 80%
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Monitoring osteoporosis treatment
Best Practice & Research: Clinical Rheumatology, 12/04/09
Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
Journal of Bone and Mineral Metabolism, 12/04/09
A perspective on male osteoporosis
Best Practice & Research: Clinical Rheumatology, 12/03/09
Sponsor
Article Search
Sponsor